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Background: Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and tensin 
homolog (PTEN) occurs in approximately 50% of patients with metastatic castration resistant 
prostate cancer (mCRPC).  Recent evidence suggests that combined inhibition of the androgen 
receptor (AR) and AKT may be beneficial in mCRPC with PTEN loss. 
 
Patients and Methods: mCRPC patients who previously failed abiraterone and/or enzalutamide, 
received escalating doses of AZD5363 (capivasertib) starting at 320mg twice daily (bid) given 4-
days on 3-days off, in combination with enzalutamide 160mg daily. The co-primary endpoints 
were safety/tolerability and determining the maximum tolerated dose (MTD) and recommended 
phase II dose; pharmacokinetics, antitumor activity, and exploratory biomarker analysis were also 
evaluated. 
 
Results: Sixteen patients were enrolled, 15 received study treatment and 13 were assessable for 
dose-limiting toxicities (DLTs).  Patients were treated at 320mg bid, 400mg bid, and 480mg bid 
dose-levels of capivasertib. The recommended phase II dose (RP2D) identified for capivasertib 
was 400mg bid, with 1/6 patients experiencing DLT (maculopapular rash) at this level. The most 
common grade ≥3 AE’s were hyperglycemia (26.7%) and rash (20%). Concomitant administration 
of enzalutamide significantly decreased plasma exposure of capivasertib, though this did not 
appear to impact pharmacodynamics. Three patients met criteria for response (defined as PSA 
decline ≥50%, CTC conversion and/or radiological response).  Responses were seen in patients 
with PTEN loss or activating mutations in AKT, low or absent AR-V7 expression, as well as those 
with an increase in pERK in post-exposure samples. 
 
Conclusions: The combination of capivasertib and enzalutamide is tolerable and has antitumor 
activity, with all responding patients harbouring aberrations in the PI3K/AKT/mTOR pathway.  
 
Clinical Trial Number:  NCT02525068 
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Key Message:  Preclinical data suggest that inhibition of both the AR and PI3K/AKT/mTOR 
signalling has synergistic activity in PTEN loss prostate cancer models.  Here we present a phase 
I clinical trial of enzalutamide combined with the AKT inhibitor capivasertib in patients with 
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metastatic CRPC and show that this regimen is safe and tolerable, with activity in some patients, 
and present correlative biomarker studies. 
 
Word Count:  3503 main body and references. 
 
Background:  
Systemic therapy for advanced prostate cancer has largely focused on targeting the androgen 
receptor (AR).  Even in castration-resistant prostate cancer (CRPC), the AR remains an important 
target, as has been unequivocally proven by the clinical success of AR pathway targeting 
therapies, such as abiraterone and enzalutamide1-3.  Despite the success of AR pathway targeted 
therapies, resistance inevitably develops and CRPC remains an incurable, lethal disease.   
 
Activation of the PI3K/AKT/mTOR pathway is one of the most common aberrations in human 
cancers, and is associated with tumor growth, survival, and drug resistance4.  Approximately 50% 
of CRPC patients have activation of this pathway, predominately due to loss of phosphatase and 
tensin homolog (PTEN)5.  Preclinical prostate cancer models with PTEN loss have demonstrated 
that a reciprocal relationship exists between the AR and PI3K/AKT/mTOR pathways, such that 
inhibition of one leads to up-regulation of the other6.  Furthermore, combined inhibition of both 
pathways result in synergistic antitumor activity in PTEN loss models, with similar results seen in 
some PTEN wildtype models7,8. 
 
AZD5363 (capivasertib) is a highly selective pan-AKT inhibitor which is undergoing investigation 
in a number of malignancies.  Two separate phase I trials in Western and Japanese populations 
found 480 mg bid 4 days on, 3 days off every week (4/7) to be the single agent recommended 
phase II dose (RP2D)9,10.  We have initiated a phase I/II trial to investigate the combination of 
enzalutamide and capivasertib in patients with metastatic CRPC.  Here we present the results of 




Patients aged ≥18 years with histologically confirmed metastatic CRPC and ECOG performance 
status 0-211, with disease progression on or after 1-2 lines of taxane based chemotherapy and 
≥12 weeks of either abiraterone or enzalutamide were eligible.  Initially, prior treatment with 
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abiraterone was mandated; however, this was amended to allow either enzalutamide or 
abiraterone due to slow accrual.  Inclusion criteria are in the Supplementary Material.  
 
Trial Oversight: 
This investigator-initiated trial was supported by a grant from AstraZeneca, endorsed by Cancer 
Research UK, and co-sponsored by The Royal Marsden NHS Foundation Trust and The Institute 
of Cancer Research. It received ethical approval from the NRES Committee London – Surrey 
Borders. The Institute of Cancer Research Clinical Trials & Statistics Unit (ICR-CTSU), London 
had responsibility for all aspects of trial management and statistical analysis. The Trial 
Management Group oversaw day-to-day trial conduct with strategic oversight provided by an 
Independent Trial Steering Committee. Safety data were reviewed, and dose escalation decisions 
made, by the Safety Review Committee.   
 
Study Objectives: 
The co-primary objectives of this study were the safety and tolerability of capivasertib in 
combination with enzalutamide, and the maximum tolerated dose (MTD) and recommended 
phase II dose (RP2D) of this combination.  Secondary objectives were antitumor activity and the 
pharmacokinetic (PK) effect of enzalutamide on capivasertib.  Exploratory objectives were 
pharmacodynamics (PD) and biomarker analyses. 
 
Study Design and Treatment: 
This was a phase I, open-label, single-centre dose escalation study with a 3+3 design12.  Based 
on prior studies9,10 capivasertib was given bid on a 4/7 schedule starting at 320 mg with a 
predefined dose escalation/de-escalation schedule (Supplementary Material).  Patients initially 
received a single dose of capivasertib on cycle 0 day 1 (C0D1) at their respective dose level 
followed by PK and PD sampling.  Patients started enzalutamide at a fixed dose of 160 mg daily 
and capivasertib at C1D1 (Supplementary Figure S1).  All cycles were 28 days in length except 
cycle 0, which was 7 days.  Dose escalation continued until dose limiting toxicity (DLT) occurred 
in ≥2/6 patients in a cohort, at which point the tolerable dose would have been exceeding.  The 
MTD and RP2D were the highest dose level with a minimum of 6 patients and fewer than one 
third experiencing DLT.  DLT criteria are in the Supplementary Material.  
   
Assessments: 
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Safety and tolerability were assessed using adverse event (AE) reporting according to Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.0.  AE reporting occurred from the 
time of first dose of study treatment to 30 days after treatment discontinuation.  Response 
assessments used PSA, bone scan, objective soft tissue assessments (RECIST v1.1), and 
circulating tumor cell (CTC) counts.  Patients were considered to have responded if (in the 
absence of contradictory evidence) any one of the following occurred: confirmed PSA decline 
≥50% from baseline; objective response according to RECIST v1.1; or circulating tumor cell (CTC) 
count conversion from ≥5/7.5mL blood at baseline to <5/7.5mL blood.  
 
Statistical Analysis of Clinical Data: 
Statistical analysis was descriptive.  AEs were tabulated and the proportion of patients with grade 
3/4 toxicities and the number and type of serious adverse events (SAEs) were reported. Patients 
receiving any study treatment were included in the safety analysis.  Patients who received at least 
12 weeks of combination treatment or discontinued prior due to progression were included in 
response analysis. Response rates by each criterion, and overall, were calculated with a 95% 
confidence interval. 
 
Research Sample Collection and Analysis: 
Venous blood samples for PK of capivasertib were taken sequentially up to 48-hours post dose 
on C0D1, C2D1, C2D4, and C2D11.  PK parameters analyzed included maximum plasma 
concentration (Cmax), time to reach Cmax (Tmax), and area under the plasma concentration time 
curve (AUC8h).  Geometric means of dose normalized Cmax and AUC8h on cycle 2 (combination 
with enzalutamide) were compared to that of cycle 0 (capivasertib alone).  Platelet rich plasma 
(PRP) and hair follicles were taking for PD analysis of biomarkers of AKT inhibition including 
phosphorylated (p) Ser9 and total GSK3β, and pThr246 and total PRAS40. Statistical analysis of 
PD samples used one way ANOVA with Kruskal Wallis post hoc test and Dunnetts multiple 
comparison test, with a p-value of <0.05 meeting significance. Samples taken at screening, on 
treatment, and at progression for biomarker analysis including next generation sequencing (NGS), 
PTEN immunohistochemistry (IHC), androgen receptor splice variant 7 (ARv7) IHC, ARv7 CTC 
mRNA quantification, and phosphorylated extracellular signal–regulated kinases (pERK) IHC 





Sixteen patients were recruited from December 2014 to May 2016, with 15 receiving study 
treatment.  Two patients were not assessable for dose-escalation decisions:  one withdrew 
consent prior to completing the DLT window without experiencing a DLT and one had dose delays 
during the DLT window for non-drug related AE’s.  At the time of data cut off (10 March 2017) all 
patients had discontinued treatment, 12 due to progressive disease, one due to AE, and two 
withdrawing consent without experiencing disease progression. Baseline characteristics are 
presented in Table 1.  
 
Safety and Tolerability: 
At the capivasertib 320 mg dose level, three patients were treated without experiencing DLT 
(Supplementary Table S1).  Dose escalation to 480 mg occurred, with five patients treated, 4 of 
whom were evaluable for dose escalation decisions. Two patients experienced DLT of grade 3 
maculopapular rash: the first occurring at C1D13, with capivasertib held the rash resolved at 
C1D21, and capivasertib re-challenged first at 480mg on C1D22, then 320mg on C2D1, both 
times resulting in recurrent grade 2 rash followed by a 2 week interruption, with the patient 
eventually tolerating 240mg starting C2D15; the second occurring at C1D10, with capivasertib 
held the rash resolved at C1D17, and capivasertib restarted at 400mg for 3 days, then decreased 
to 360mg due to drug supply issues, with no recurrence of rash.   Dose de-escalation to an 
intermediate dose of 400mg occurred. Seven patients were treated, with 6 evaluable for DLT.  
One patient experienced a DLT of grade 3 maculopapular rash at C1D10 which resolved at 
C1D27 after capivasertib was held and the patient was able to restart capivasertib at 320mg dose 
without recurrence of rash.  Based on this data capivasertib 400 mg bid 4/7 was selected as the 
MTD and RP2D.   
 
In the safety population, 259 AEs were reported, with 42.5% of these judged to be treatment-
related. All patients experienced at least one treatment-related AE (Supplementary Table 
S2).  Grade ≥3 treatment-related AE occurred in 8 patients (53.5%), with hyperglycemia and 
maculopapular rash being the most frequent.  During the DLT period, 9 patients (60%) had a 
dosing interruption or reduction in enzalutamide, capivasertib, or both; 5 of these (55.6%) were 
due to AE’s. 14 patients continued treatment beyond cycle 1; of these, 6 patients (42.9%) had a 
dosing interruption or reduction.  Three patients remained on treatment for at least 24-weeks.  
Twelve serious adverse events (SAE) occurred in 7 patients, with four considered to be related 
to the study drug and expected: hyperglycemia (dose level 480mg); hyperglycemia and elevated 
creatinine (dose level 400mg); maculopapular rash (dose level 480mg); and nausea, anorexia, 
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and pain (dose level 320mg).  One suspected unexpected serious adverse reaction (SUSAR) 
occurred at dose level 480mg: systemic inflammatory response syndrome (grade 2) that was felt 
to be probably related to capivasertib and resolved after drug interruption, and did not recur upon 
re-challenge.  There were no fatal SAEs. 
 
Antitumor activity: 
Ten patients completed 12-weeks of study treatment and two patients discontinued prior to week 
12 due to progressive disease (Figure 1, Supplementary Table S5).  Therefore twelve patients 
were considered evaluable for response (Supplementary Table S6).   Of the twelve evaluable 
patients, 11 were evaluable by PSA, 9 by RECIST v1.1, and 8 by CTC enumeration.    Three 
patients met at least one response criteria, with only one showing conflicting response criteria 
(conversion of CTC count to <5/7.5mL whole blood, but a rising PSA).  One of these patients, 
who previously had progressive disease on both abiraterone and enzalutamide, met all three 
response criteria and remained on treatment for 25 weeks.  Additionally, one patient who withdrew 
consent prior to completing the first cycle of combination therapy, had a 41.4% PSA reduction at 
4-weeks. 
 
Pharmacokinetics and pharmacodynamics: 
Administration of enzalutamide decreased both Cmax and AUC of capivasertib in 11 out of 13 
patients when compared with capivasertib monotherapy (approximately mean 40% decrease at 
cycle 2 compared with cycle 0) (Supplementary Tables S3 and S4).  Following dose 
normalization to 320mg, the geometric means were significantly different (based on 90% CI).  It 
should be noted that the overall inhibition of capivasertib by enzalutamide is greater than 40% 
given the accumulation that occurs over 4 weeks of administration.  Noticeably, the predose levels 
on cycle 2 day 1 ranged from 51 to 483ng/ml (data not shown).  The administration of ADZ5363 
with and without enzalutamide, resulted in variable but notable decrease in pGSK3β in PRP at all 
dose levels at 4h post dose (Percentage decrease at 320mg without  enzalutamide (-) 61 to 96%, 
with enzalutamide (+) 63 to 82%, 400mg - 20 to 70%  + 5 to 65%, 480mg - 42 to 73% + 14 to 
78%; No significant difference p=0.3880 one way ANOVA with Kruskal Wallis post hoc test) 
(Supplementary Figure S4A).  In patients treated with 400mg, a significant reduction of >20% 
was observed in pGSK3β at 2 (mean decrease 56%) and 4h (44%) post-dose compared to base-
line when AZD5363 was administered alone (cycle 0) (p=0.0086 One way repeated measures 
ANOVA with Dunnetts multiple comparison test), though pGSK3β returned to baseline at 8 hours 
post dose (mean decrease 22%) and beyond (Supplementary Figure S4B). Furthermore, 
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decreases in pPRAS40 from hair follicle samples were also measured at cycles 0 and 2 
(Percentage decrease at 320mg without enzalutamide (-) 31-46%, with enzalutamide (+) -101 to 
33%, 400mg - 6 to 53%, + 19 to 61%, 480mg - 18 to 52%, + -19 to 59%; Not significant p=0.8647 
one way ANOVA with Kruskal wallis post hoc test) (Supplementary Figure S5).  Despite, the 
decreased exposure of AZD5363 in the presence of enzalutamide the inhibition of GSK3β and 
PRAS40 phosphorylation were not significantly lower than that observed with AZD5363 alone for 
example mean percentage reduction in PRAS40  38, 26, 23% without enzalutamide and -34, 40 
and 22% with enzalutamide for the doses 320, 480, 400 mg respectively.    
 
Exploratory Endpoints:  
PTEN loss was found in 6 of 16 patients, while targeted NGS identified pathogenic mutations in 
PI3K/AKT/mTOR pathway genes in 2 of 15 (Figure 1 and Supplementary Table S5). In the three 
responders, two had PTEN loss by IHC, with the third PTEN normal and harboring an activating 
AKT E17K mutation (Supplementary Table S5).  Another patient who had a ≥30% PSA response 
at 4-weeks, but withdrew from the trial prior to completing the 35-day DLT window, was found to 
be PTEN normal and to have a PIK3CA I391M single nucleotide aberration of uncertain 
significance. 
 
AR-V7 status by IHC was available for 14 patients at baseline and 13 post-treatment.  AR-V7 
mRNA expression in CTC’s by AdnaTest was available for 14 patients at baseline and 6 post- 
treatment.  CTC’s were present in 10 of 14 patients at baseline.  All patients who were negative 
for AR-V7 expression by IHC at baseline were either negative for AR-V7 mRNA expression in 
CTC’s by AdnaTest, or CTC negative.  Similarly, all patient with detectable AR-V7 mRNA in CTC’s 
at baseline were positive for AR-V7 by IHC; however, the absence of AR-V7 mRNA in CTC’s was 
not predictive of the absence of AR-V7 expression by IHC (supplementary material).  The 
AdnaTest for AR-V7 was positive in 3 patients, all of whom were non-responders.  In responding 
patients, at baseline 2 had detectable CTC’s with no detection of AR-V7, and 1 had no CTC’s 
detected.  AR-V7 expression at baseline appeared to predict lack of benefit, with IHC for AR-V7 
positive in one responder, though at very low levels (Supplementary Figures S7 and S8).  Post 
treatment, CTC’s were detected in 3 patients who were CTC negative at baseline, with AR-V7 
detected in 2 of these patients.  pERK expression by IHC was low or absent in all but two patients 
at baseline and increased post treatment in 3 patients, including 2 of the responders 




Clinically validated biomarkers have yet to be introduced in mCRPC, though several candidates 
appear poised to change this paradigm with early studies showing AR-V7 associating with poor 
outcome to AR targeted therapies13, and DNA damage response (DDR) gene and mismatch 
repair (MMR) defects predicting response to PARP inhibitors14 and immunotherapy 
respectively15,16.  Activation of the PI3K/AKT/mTOR pathway through PTEN loss is one of the 
most common molecular events in CRPC and has been proposed as a mechanism of resistance 
to AR targeted therapies4,6,17-19 with preclinical studies showing synergistic antitumor activity with 
combined AR and PI3K/AKT/mTOR pathway inhibition6-8.   
 
Here we demonstrate the safety and tolerability of co-targeting AR and AKT signaling with 
enzalutamide and capivasertib in mCRPC patients.  While enzalutamide significantly lowered 
plasma concentrations of capivasertib, this did not appear to compromise the PD effect, with 
similar, albeit variable, modulation of GSK3β and PRAS40 phosphorylation both in the presence 
and absence of enzalutamide.  Furthermore, the adverse events typical of capivasertib such as 
maculopapular rash, hyperglycemia, and diarrhea, occurred frequently, with the RP2D found in 
this study of 400mg bid 4/7, being in fact lower than that found in two separate single agent phase 
I studies of this compound9,10, though the same as when combined with paclitaxel20. 
 
We identified antitumor activity in this heavily pretreated population.  All patients meeting 
response criteria had pathogenic events within the PI3K/AKT/mTOR pathway.  Baseline AR-V7 
expression by AdnaTest and IHC appeared to predict resistance to this combination, similar to 
what has been demonstrated with AR targeted therapy alone13,21.  Another putative predictive 
biomarker of AKT inhibition may be extracellular signal-regulated kinase (ERK)22,23.  AKT 
negatively regulates ERK activation through the phosphorylation of N-terminus inhibitory sites of 
Raf24-27, therefore inhibition of AKT releases cross-inhibition of Raf and increases phosphorylation 
of ERK. We found that among patients with evaluable pre- and post-treatment biopsies, IHC 
pERK score substantially increased in responders. 
 
Interestingly, a recent randomized phase II trial of abiraterone with or without the AKT inhibitor 
ipatasertib provides additional support for co-targeting the AR and AKT.  This study demonstrated 
improved rPFS in the overall population, though subgroup analysis demonstrated a marked 
benefit for PTEN loss patients relative to PTEN normal28.  Of note, ipatasertib was given 
continuously, whereas in the current study, capivasertib was given on a 4/7 intermittent schedule, 
10 
based on the single agent phase I study demonstrating favorable tolerability, PK profile, and target 
engagement compared to other schedules9, and supported by preclinical PK-PD efficacy 
mathematical modelling29.  Whether this results in clinically relevant differences in antitumour 
activity is not known.  Co-targeting of the AR and AKT may be a viable strategy in PTEN loss 
mCRPC, though further validation is required. 
 
In conclusion, co-targeting of the AR and AKT with enzalutamide and capivasertib is safe with 
preliminary evidence of anti-tumor activity, supporting the ongoing Phase II portion of this trial.  
All responding patients in this study had aberrations in the PI3K/AKT/mTOR pathway and absent 
or low AR-V7 expression at baseline, with two of the three responders showing an increase in 
pERK expression post treatment.  However, due to the small sample size, further study is required 
to determine the potential value of these as predictive biomarkers for this combination. 
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Figure 1:  Percent change in PSA at 12 weeks relative to baseline PSA.  Each bar represents an 
individual patient.  Light grey indicates the patient previously received treatment with both 
abiraterone and enzalutamide; dark grey indicates prior treatment with only abiraterone and not 
enzalutamide.  Patients indicated with (✖︎) discontinued before 12 weeks but safety follow up 
results are available; in these patients, the percent change of PSA at discontinuation relative to 
baseline is presented.  The patient indicated with (✚) also met response criteria for RECIST and 
CTC conversion.  Patients indicated with (●) discontinued treatment prior to 12 weeks with no 
post-treatment PSA values obtained.  Dose level refers to the dosage of capivasertib the patient 
received in mg.  PTEN status refers to IHC expression with N representing normal, and L 
representing loss.  ARV7 status refers to pretreatment tumor biopsy baseline AR-V7 expression 
by IHC, with + indicating an H-score of >10, and - indicating an ≤10.  pERK refers to increased 
15 
expression by IHC on post treatment tumor biopsy samples relative to baseline indicated by (+), 
whereas (-) indicates no increase.  NGS refers to next generation sequencing, with (+) 
representing known or likely deleterious mutations in PI3K/AKT/mTOR pathway genes, and (-) 
representing an absence of such mutations.  NA indicates not available.  Patients meeting 
response criteria assessed by PSA, soft tissue objective response by RECIST, CTC conversions, 
and overall (indicated by (-r) respectively) are indicated by (Yes), with non-responders indicated 
by (No), and (N/E) indicating non-evaluable. † indicates non-confirmed CTC conversions. 
Reasons for discontinuation included progressive disease (PD), patient choice (PC), and adverse 
events (AE).  
 
 
